---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-301414"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2026-07-13T10:30:23+00:00"
generated_at: "2026-07-13T10:35:19.930314+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Agenus raises $85M upfront (up to $340M) to fund registrational Phase 3 ROBBIN trial of BOT+BAL in MSS colon cancer

## Summary
- Private placement of $85M upfront gross proceeds, plus up to $255M from warrant exercise; total up to $340M.
- Proceeds to fund ROBBIN Phase 3 trial in neoadjuvant MSS colon cancer; expected runway through year-end 2031 if warrants exercised.
- ROBBIN trial to enroll 850 patients, primary endpoint EFS; first patient dosed Q1 2027, interim pathologic response data H2 2027.
- Discontinuing financial support for BATTMAN Phase 3 in late-line metastatic MSS CRC.
- Phase 2 data: pathologic response ~60-70%, MPR ~35-40%, pCR ~30%; all patients disease-free at median 9-18 months follow-up.

## SEC filing metadata
- accession: 0001193125-26-301414
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2026-07-13T10:30:23+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000119312526301414/0001193125-26-301414-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000119312526301414/d111026d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-301414
- JSON: https://secwatch.observer/filing/0001193125-26-301414.json
- Plain text: https://secwatch.observer/filing/0001193125-26-301414.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.